XML 62 R46.htm IDEA: XBRL DOCUMENT v3.6.0.2
Collaborative Agreements Collaborative Agreements (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Jul. 28, 2016
Aug. 07, 2015
USD ($)
product
Nov. 14, 2014
Apr. 30, 2015
USD ($)
Sep. 30, 2013
USD ($)
Dec. 31, 2016
USD ($)
Sep. 30, 2016
USD ($)
Jun. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Revenue under collaborative research and development arrangements           $ 476,586 $ 2,327,316 $ 1,889,988 $ 1,796,857 $ 1,820,643 $ 16,475,083 $ 4,335,236 $ 4,245,571 $ 6,490,747 $ 26,876,533 $ 7,416,568
Collaborative Arrangement, Product                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Upfront payment received         $ 10,000,000                      
MedImmune | Collaborative Arrangement, Product                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Upfront payment received   $ 27,500,000                            
Anticipated development and regulatory event based payment receivable milestones   $ 700,000,000                            
Number of additional products | product   2                            
Revenue under collaborative research and development arrangements                           1,500,000 16,000,000  
Deferred revenue           13,700,000       13,000,000       13,700,000 13,000,000  
Accounts receivable           1,200,000       1,500,000       1,200,000 1,500,000  
Roche | Collaborative Arrangement, Product                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Upfront payment received         10,000,000                      
Anticipated development and regulatory event based payment receivable milestones         3,000,000                   3,000,000  
Revenue under collaborative research and development arrangements                           4,900,000 10,800,000  
Deferred revenue           0       166,000       0 166,000  
Accounts receivable           2,400,000       1,600,000       2,400,000 1,600,000  
Previously deferred revenue recognized                             3,000,000  
DARPA | Collaborative Arrangement, Product                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Deferred revenue           1,200,000       283,000       1,200,000 283,000  
Accounts receivable           $ 9,200,000       $ 4,000,000       9,200,000 4,000,000  
Previously deferred revenue recognized                           $ 22,400,000 $ 0  
Term       2 years                        
Base award       $ 19,600,000                        
Option award       24,600,000                        
Second option award       $ 11,100,000                        
INO-3112 | Collaborative Arrangement, Product                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Revenue recognized   $ 15,000,000                            
INO 1800 | Collaborative Arrangement, Product                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Revenue recognized         3,400,000                      
INO 5150 | Collaborative Arrangement, Product                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Revenue recognized         5,000,000                      
INO 5150 | Roche | Collaborative Arrangement, Product                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Period after notice when termination is effective 90 days   90 days                          
Nonsoftware License Arrangement | License To Research Collaboration Products | Collaborative Arrangement, Product                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Deferred revenue, additions   $ 12,500,000                            
Nonsoftware License Arrangement | Option Right | Collaborative Arrangement, Product                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Deferred revenue, additions         1,500,000                      
Nonsoftware License Arrangement | Joint Steering Committee Obligation | Collaborative Arrangement, Product                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Deferred revenue, additions         $ 155,000